Armata Pharmaceuticals Files 8-K

TL;DR

Armata Pharma filed an 8-K on 3/22/24 covering shareholder nominations and financials.

AI Summary

Armata Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, reporting on shareholder nominations and financial statements. The company, formerly AmpliPhi Biosciences Corp, is incorporated in Washington and headquartered in Los Angeles, California.

Why It Matters

This filing provides updates on corporate governance and financial reporting for Armata Pharmaceuticals, Inc.

Risk Assessment

Risk Level: low — This is a routine filing reporting standard corporate actions and financial information.

Key Players & Entities

• Armata Pharmaceuticals, Inc. (company) — Registrant
• March 22, 2024 (date) — Filing Date
• AmpliPhi Biosciences Corp (company) — Former Company Name
• Los Angeles, California (location) — Principal Executive Office

FAQ

Filing Documents

• tm249318d1_8k.htm (8-K) — 26KB
• 0001104659-24-037578.txt ( ) — 194KB
• armp-20240322.xsd (EX-101.SCH) — 3KB
• armp-20240322_lab.xml (EX-101.LAB) — 33KB
• armp-20240322_pre.xml (EX-101.PRE) — 22KB
• tm249318d1_8k_htm.xml (XML) — 3KB

08

Item 5.08 Shareholder Director Nominations Armata Pharmaceuticals, Inc. ("Armata" or the "Company") has set June 12, 2024 as the date for its 2024 annual meeting of stockholders (the "Annual Meeting"). The Annual Meeting will be held at 8:30 a.m. (Pacific Time), via virtual web service, to be announced publicly prior to the Annual Meeting, or at such other time and location to be determined by the Company's Board of Directors and set forth in the Company's proxy notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting. Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Armata's 2023 annual meeting of stockholders, Armata has set new deadlines for (i) the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), for inclusion in Armata's proxy materials for the Annual Meeting ("Rule 14a-8 Deadline") and (ii) receipt of stockholder proposals and director nominations submitted pursuant to Article II, Section 2.6 of Armata's Amended and Restated Bylaws for consideration at the Annual Meeting ("Advance Notice Bylaws Provision Deadline"). The Rule 14a-8 Deadline is 5:00 p.m. (Eastern Time) on Monday, April 1, 2024, which Armata has determined to be a reasonable period of time before it expects to begin to print and send its proxy materials. The Advance Notice Bylaws Provision Deadline is 5:00 p.m. (Eastern Time) on Monday, April 1, 2024. Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata's principal executive offices at Armata Pharmaceuticals, Inc., 5005 McConnell Avenue, Los Angeles, California 90066, by the Rule 14a-8 Deadline or the Advance Notice Bylaws Provision Deadline, as applicable, in order

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within Inline XBRL document). - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 22, 2024 Armata Pharmaceuticals, Inc. By: /s/ Richard Rychlik Name: Richard Rychlik Title: Principal Financial Officer and Corporate Controller - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR